HUF North America Invests $20 Million To Expand Greeneville, Tennessee, Manufacturing Complex
01/31/2013
The company will add a 52,000 square foot addition to its current structure for a plastic injection molding and paint facility. The expansion is expected to be complete in 2013, with customer deliveries beginning in 2014.
“Huf North America is excited to announce the business and process expansion at our Greeneville, Tenn. location to include plastic injection molding and paint, which will create 100 new jobs,” Michael Supe, president and CEO, Huf North America, said. “Our Tennessee location was established in 1995 and is considered a central logistic location for the Huf Group, supplying German and U.S. original equipment manufacturers. The expansion completion date is planned for the end of 2013, starting customer deliveries at the beginning of 2014. The annual planned volume is 2.5 million vehicles.”
“Our Jobs4TN Plan made expanding existing businesses in Tennessee one of our priorities, and it identified the automotive industry as one of six key clusters in which Tennessee has a distinct competitive advantage we could leverage for job growth,” Gov. Bill Haslam said. “Huf North America has been a part of Tennessee’s business community for nearly two decades, and I want to congratulate the company on its ongoing success.”
“Tennessee is an attractive location for companies around the world with our business friendly environment, solid workforce and tradition of quality manufacturing,” Economic and Community Development Commissioner Bill Hagerty. “I thank Huf North America for its continued investment and confidence in our state and its citizens.”
Most Read
-
-
On the Hunt for a Productive New Biomanufacturing Site?
Q4 2021
-
Changes in the Incentives Landscape
Q3 2021
-
Solutions for Decisively Navigating the Location Decision
Q4 2021
-
Labor Challenges in the Industrial and Manufacturing Sectors Persist
Workforce Q4 2021
-
The Challenges of Renovating an Existing Facility Into a Food Plant
Q4 2021
-
Location Factors for Cell and Gene Therapy Companies
Q4 2021